



New Perspectives on Chronic Kidney Disease

Guest Editor:

Dr. Ewelina Młynarska

Department of
Nephrocardiology, Medical
University of Lodz, ul.
Żeromskiego 113, 90-549 Lodz,
Poland

Deadline for manuscript
submissions:

30 November 2024

Message from the Guest Editor

Chronic kidney disease is a progressive condition that affects more than 10% of the general population worldwide. Early detection plays a critical role in preventing the onset of kidney failure. Physicians assess patients for indicators of renal disease and perform a range of diagnostic tests to evaluate kidney function, including measurements such as serum creatinine level, cystatin C, blood urea nitrogen, glomerular filtration rate (eGFR), electrolyte levels, and red blood cell count, as well as urinalysis. On occasion, a biopsy of kidney tissue may be required for accurate diagnosis. To date, these tests have represented the standards for the diagnostics of kidney diseases. However, new technologies offer promising new ways to diagnose and prognose kidney diseases. Biomarkers other than plasma creatinine and the glomerular filtration rate are becoming crucial for the diagnosis and assessment of a patient's condition. New diagnostic methods play a significant role in diagnosis and provide greater treatment options.

This Special Issue aims to present recent advances in chronic kidney disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI